MAPK14 and metabolic syndrome: Crocetin also augmented lipid profile toward standard value, and co-administration of crocetin with simvastatin certificated dyslipidemia, through increased anti-oxidant activity and inhibition of phosphorylated p38 mitogen-activated protein kinase (MAPK) (65).